Achieve Life Sciences (NASDAQ:ACHV) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.28) by $0.57, Fidelity Earnings reports.
Shares of Achieve Life Sciences stock traded down $0.01 during trading hours on Friday, hitting $2.07. The company’s stock had a trading volume of 74,464 shares, compared to its average volume of 440,980. Achieve Life Sciences has a 12-month low of $1.85 and a 12-month high of $32.00. The company has a market capitalization of $10.24 million, a price-to-earnings ratio of -0.09 and a beta of 2.28.
Separately, LADENBURG THALM/SH SH started coverage on Achieve Life Sciences in a research report on Monday, August 20th. They issued a “buy” rating and a $12.00 price objective on the stock.
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.
Featured Article: Hedge Funds – How They Work For Investors
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.